Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer.

Authors:
Ryan Ross
Ryan Ross
The College of New Jersey
United States
Paul Lin
Paul Lin
Chang Gung Memorial Hospital
Taiwan
Bhramar Mukherjee
Bhramar Mukherjee
University of Michigan
United States

JAMA Netw Open 2019 Apr 5;2(4):e192589. Epub 2019 Apr 5.

Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor.

Importance: Sipuleucel-T is an immunotherapy that has been approved for use in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). However, sipuleucel-T may not be available to some patients because of logistics, cost, and practice structure.

Objective: To identify factors associated with the adoption of sipuleucel-T across the United States.

Design, Setting, And Participants: In this retrospective cohort study, patients with prostate cancer who received therapy for mCRPC (docetaxel, abiraterone acetate, enzalutamide, cabazitaxel, radium 223, or sipuleucel-T) from January 1, 2010, through June 30, 2016, were identified in a large claims database of commercially insured patients. Patients who received sipuleucel-T were compared with patients who received any of the other treatments for mCRPC but did not receive sipuleucel-T. Data were analyzed from May 3, 2018, to February 24, 2019.

Exposures: Sipuleucel-T treatment.

Main Outcomes And Measures: Patterns of treatment that involved the use of sipuleucel-T were elucidated, and binomial logistic regression was conducted to determine patient and physician factors that were associated with the use of sipuleucel-T and whether patients received sipuleucel-T in isolation or concurrently with other therapies.

Results: Among 7272 patients who received a treatment for mCRPC, 730 (10.0%) received sipuleucel-T. Mean (SD) age of patients in the entire cohort was 73.2 (9.2) years; 6739 (92.7%) were non-Hispanic and 975 (13.4%) were black. In multivariable analysis, patients who were Hispanic (odds ratio [OR], 0.57; 95% CI, 0.38-0.86) or lived in the Pacific region (OR, 0.66; 95% CI, 0.45-0.97) had lower odds of receiving sipuleucel-T than patients who were not Hispanic or who lived in the South Atlantic region. Patients with higher incomes had greater odds of receiving sipuleucel-T than patients with incomes of less than $50 000 (OR, 1.29 [95% CI, 1.04-1.61] for $50 000-$99 000; OR, 1.43 [95% CI, 1.10-1.85] for >$99 000). Patients treated by a urologist had greater odds of receiving sipuleucel-T than patients not treated by a urologist (OR, 8.89; 95% CI, 7.10-11.11). Sixty-seven patients received concurrent therapies with sipuleucel-T, most commonly abiraterone or enzalutamide, but no factors were independently associated with patients receiving sipuleucel-T concurrent with other therapies for mCRPC.

Conclusions And Relevance: In this study, 1 of 10 patients with prostate cancer who were treated for mCRPC received sipuleucel-T, with several variables associated with its use. Identifying disparities in receipt of sipuleucel-T may affect future access to this and other highly specialized cancer therapies by defining barriers to treatment that could be addressed in future studies.

Download full-text PDF

Source
http://jamanetworkopen.jamanetwork.com/article.aspx?doi=10.1
Publisher Site
http://dx.doi.org/10.1001/jamanetworkopen.2019.2589DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481456PMC
April 2019
7 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
May 13, 2019, 9:30 am EST
twitter
Twitter:
April 26, 2019, 4:06 pm EST
twitter
Twitter:
April 24, 2019, 3:20 pm EST
twitter
Twitter:
April 24, 2019, 3:19 pm EST
twitter
Twitter:
April 24, 2019, 3:00 pm EST
twitter
Twitter:
April 24, 2019, 10:02 am EST
twitter
Twitter:
April 24, 2019, 10:00 am EST
twitter
Twitter:
April 24, 2019, 8:00 am EST
twitter
Twitter:
April 23, 2019, 8:00 am EST
twitter
Twitter:
April 21, 2019, 8:45 pm EST
twitter
Twitter:
April 21, 2019, 1:04 pm EST
twitter
Twitter:
April 21, 2019, 9:13 am EST
twitter
Twitter:
April 21, 2019, 7:56 am EST
twitter
Twitter:
April 21, 2019, 12:36 am EST
twitter
Twitter:
April 20, 2019, 7:01 pm EST
twitter
Twitter:
April 20, 2019, 7:00 pm EST
twitter
Twitter:
April 20, 2019, 6:31 pm EST
twitter
Twitter:
April 20, 2019, 4:33 pm EST
twitter
Twitter:
April 20, 2019, 4:04 pm EST
twitter
Twitter:
April 20, 2019, 3:30 pm EST
twitter
Twitter:
April 20, 2019, 2:59 pm EST
twitter
Twitter:
April 20, 2019, 2:37 pm EST
twitter
Twitter:
April 20, 2019, 2:36 pm EST
twitter
Twitter:
April 20, 2019, 2:28 pm EST
twitter
Twitter:
April 20, 2019, 2:24 pm EST
twitter
Twitter:
April 20, 2019, 2:22 pm EST
twitter
Twitter:
April 20, 2019, 2:12 pm EST
twitter
Twitter:
April 20, 2019, 2:09 pm EST
twitter
Twitter:
April 20, 2019, 1:12 pm EST
twitter
Twitter:
April 20, 2019, 1:00 pm EST
twitter
Twitter:
April 20, 2019, 12:41 pm EST
twitter
Twitter:
April 20, 2019, 12:28 pm EST
twitter
Twitter:
April 20, 2019, 10:29 am EST
twitter
Twitter:
April 20, 2019, 10:21 am EST
twitter
Twitter:
April 20, 2019, 9:25 am EST
twitter
Twitter:
April 20, 2019, 9:23 am EST
twitter
Twitter:
April 20, 2019, 7:13 am EST
twitter
Twitter:
April 19, 2019, 10:00 pm EST
twitter
Twitter:
April 19, 2019, 6:43 pm EST
twitter
Twitter:
April 19, 2019, 2:07 pm EST
twitter
Twitter:
April 19, 2019, 2:04 pm EST
twitter
Twitter:
April 19, 2019, 1:28 pm EST
twitter
Twitter:
April 19, 2019, 1:28 pm EST

Publication Analysis

Top Keywords

patients received
20
sipuleucel-t patients
20
sipuleucel-t
19
patients
19
received sipuleucel-t
16
prostate cancer
16
receiving sipuleucel-t
16
factors associated
12
odds receiving
12
patients hispanic
8
study patients
8
concurrent therapies
8
associated sipuleucel-t
8
treated urologist
8
patients treated
8
patients prostate
8
greater odds
8
received
8
mcrpc
5
cancer
5

Similar Publications